These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 10828867)

  • 1. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
    Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
    Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.
    Basara N; Blau WI; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
    Bone Marrow Transplant; 1998 Jul; 22(1):61-5. PubMed ID: 9678797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
    Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
    Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
    Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients.
    Baudard M; Vincent A; Moreau P; Kergueris MF; Harousseau JL; Milpied N
    Bone Marrow Transplant; 2002 Sep; 30(5):287-95. PubMed ID: 12209350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
    Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings.
    Vogelsang GB; Arai S
    Bone Marrow Transplant; 2001 Jun; 27(12):1255-62. PubMed ID: 11548843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus.
    Mookerjee B; Altomonte V; Vogelsang G
    Bone Marrow Transplant; 1999 Sep; 24(5):517-20. PubMed ID: 10482936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.
    Hebert MF; Ascher NL; Lake JR; Emond J; Nikolai B; Linna TJ; Roberts JP
    Transplantation; 1999 Mar; 67(5):707-12. PubMed ID: 10096526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
    Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
    Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prophylaxis and treatment of chronic graft versus host disease].
    Huang K; Li Y; Huang SL; Fang JP; Zhou DH; Chen C
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):174-7. PubMed ID: 15833186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
    Bornhäuser M; Schuler U; Pörksen G; Naumann R; Geissler G; Thiede C; Schwerdtfeger R; Ehninger G; Thiede HM
    Transplantation; 1999 Feb; 67(4):499-504. PubMed ID: 10071016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation.
    Hambach L; Stadler M; Dammann E; Ganser A; Hertenstein B
    Bone Marrow Transplant; 2002 Jun; 29(11):903-6. PubMed ID: 12080355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients.
    Basara N; Blau WI; Kiehl MG; Schmetzer B; Bischoff M; Kirsten D; Günzelmann S; Fauser AA
    Clin Transplant; 2000 Apr; 14(2):121-6. PubMed ID: 10770416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.